GleamWall
中文EN

RXRX RECURSION PHARMACEUTICALS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—

Margins

Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%

Returns

ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.55M$7.67M$6.47M$35.54M$5.17M$19.22M$14.74M$4.55M
Cost of revenue$10.04M$11.49M$12.49M$14.28M$14.69M$20.16M$21.83M$12.79M
Gross profit$8.51M-$3.82M-$6.02M$21.26M-$9.51M-$938,000-$7.08M-$8.25M
R&D expense$99.12M$89.61M$87.90M$95.94M$121.06M$128.64M$129.63M$98.33M
SG&A expense$32.56M$41.53M$34.59M$33.66M$41.63M$46.65M$54.65M$77.19M
Operating income-$123.18M-$134.97M-$128.50M-$108.33M-$172.20M-$176.23M-$191.37M-$183.77M
Interest expense$266,000$309,000$350,000-$11,000$833,000$480,000$508,000$605,000
Pretax income-$119.01M-$131.01M-$122.11M-$108.10M-$162.25M-$171.90M-$202.65M-$178.90M
Income tax$25,000-$1,000-$4.60M$20,000$3,000$0-$158,000$7,000
Net income-$119.04M-$131.00M-$117.50M-$108.12M-$162.25M-$171.90M-$202.49M-$178.91M
EBITDA-$106.64M-$116.80M-$108.83M-$88.86M-$151.16M-$152.38M-$172.04M-$170.82M
EPS (basic)-0.22-0.25-0.22—-0.36-0.41-0.50—
EPS (diluted)-0.22-0.25-0.22—-0.36-0.41-0.50—
Weighted avg. shares (diluted)543.00M532.46M529.30M—446.99M417.36M402.77M—
Balance sheet
Cash & equivalents$549.85M$545.68M$654.47M$743.29M$667.14M$533.85M$509.16M$603.02M
Current assets$616.02M$603.46M$709.56M$812.85M$714.11M$587.16M$584.14M$714.27M
PP&E, net$85.84M$89.62M$95.81M$103.93M$111.71M$120.04M$126.83M$141.06M
Goodwill$160.71M$160.35M$160.17M$162.16M$162.04M$164.27M$158.11M$148.87M
Intangibles$273.68M$282.89M$294.07M$309.90M$322.34M$341.32M$335.79M$335.86M
Total assets$1.22B$1.21B$1.34B$1.47B$1.40B$1.30B$1.31B$1.45B
Current liabilities$122.92M$119.89M$129.70M$147.71M$155.10M$164.03M$141.98M$187.47M
Short-term debt$11.81M$9.44M$9.27M$9.09M$8.92M$8.75M$8.59M$8.43M
Long-term debt$93,000$4.75M$7.18M$9.56M$11.90M$14.20M$16.45M$19.02M
Total debt$11.90M$14.20M$16.45M$18.66M$20.82M$22.95M$25.03M$27.45M
Total liabilities$315.90M$297.67M$314.75M$343.26M$352.58M$383.21M$371.29M$413.82M
Shareholders' equity$905.81M$915.00M$1.02B$1.13B$1.05B$919.15M$933.95M$1.03B
Net debt-$537.95M-$531.49M-$638.03M-$724.64M-$646.32M-$510.90M-$484.12M-$575.58M
Shares outstanding561.07M534.12M530.63M528.18M491.80M432.83M406.41M396.80M
Cash flow statement
Operating cash flow-$77.41M-$105.95M-$81.10M-$46.07M-$117.36M-$76.42M-$131.96M-$115.43M
Capital expenditure$407,000$44,000$258,000$1.24M$243,000$3.15M$1.83M$1.30M
Free cash flow-$77.81M-$105.99M-$81.36M-$47.32M-$117.60M-$79.57M-$133.79M-$116.73M
Investing cash flow-$407,000-$1.96M-$338,000-$1.24M-$2.55M-$5.81M-$7.27M$275.46M
Financing cash flow$83.14M-$1.27M-$3.47M$132.01M$251.34M$97.66M$40.53M$10.64M
Depreciation & amortization$16.54M$18.17M$19.67M$19.48M$21.04M$23.85M$19.33M$12.95M
Stock-based compensation$23.03M$19.30M$22.21M$23.76M$25.04M$25.80M$36.06M$30.78M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.